Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 220

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule

Tolmachev, Vladimir, Orlova, Anna, Pehrson, Rikard, Galli, Joakim, Baastrup, Barbro, Andersson, Karl, Sandström, Mattias, Rosik, Daniel, Carlsson, Jörgen, Lundqvist, Hans, Wennborg, Anders, Nilsson, Fredrik Y. · 2007 · Cancer Research

Abstract

A radiolabeled anti-HER2 Affibody molecule (ZHER2:342) targets HER2-expressing xenografts with high selectivity and gives good imaging contrast. However, the small size (∼7 kDa) results in rapid glomerular filtration and high renal accumulation of radiometals, thus excluding targeted therapy. Here, we report that reversible binding to albumin efficiently reduces the renal excretion and uptake, enabling radiometal-based nuclide therapy. The dimeric Affibody molecule (ZHER2:342)2 was fused with an albumin-binding domain (ABD) conjugated with the isothiocyanate derivative of CHX-A″-DTPA and labeled with the low-energy β-emitter 177Lu. The obtained conjugate [CHX-A″-DTPA-ABD-(ZHER2:342)2] had a dissociation constant of 18 pmol/L to HER2 and 8.2 and 31 nmol/L for human and murine albumin, respectively. The radiolabeled conjugate displayed specific binding to HER2-expressing cells and good cellular retention in vitro. In vivo, fusion with ABD enabled a 25-fold reduction of renal uptake in comparison with the nonfused dimer molecule (ZHER2:342)2. Furthermore, the biodistribution showed high and specific uptake of the conjugate in HER2-expressing tumors. Treatment of SKOV-3 microxenografts (high HER2 expression) with 17 or 22 MBq 177Lu-CHX-A″-DTPA-ABD-(ZHER2:342)2 completely prevented formation of tumors, in contrast to mice given PBS or 22 MBq of a radiolabeled non–HER2-binding Affibody molecule. In LS174T xenografts (low HER2 expression), this treatment resulted in a small but significant increase of the survival time. Thus, fusion with ABD improved the in vivo biodistribution, and the results highlight 177Lu-CHX-A″-DTPA-ABD-(ZHER2:342)2 as a candidate for treatment of disseminated tumors with a high level of HER2 expression. [Cancer Res 2007;67(6):2773–82]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-06-1630

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 220

Metadata

Authors
Tolmachev, V., Orlova, A., Pehrson, R., Galli, J., Baastrup, B., Andersson, K., Sandström, M., Rosik, D., Carlsson, J., Lundqvist, H., Wennborg, A., & Nilsson, F. Y.
Venue
Cancer Research
Published
2007-03-15
Volume
67
Issue
6
Pages
2773-2782
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W1985312565
Cited by
220
References
2
FWCI
15.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-1630
The paper
Tolmachev, V., Orlova, A., Pehrson, R., Galli, J., Baastrup, B., Andersson, K., Sandström, M., Rosik, D., Carlsson, J., Lundqvist, H., Wennborg, A., & Nilsson, F. Y. (2007). Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-1630

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.